Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 1:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 51 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Razadyne Clear all
Recruiting Phase 4 Interventional

A Study of Zunveyl on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Alzheimer's Disease (RESOLVE)

NCT07633470
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Zunveyl®
Drug
Lead sponsor
Alpha Cognition, Inc
Industry
Eligibility
50 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
22
States / cities
Irvine, California • Orange, California • Aventura, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 24, 2026, 1:50 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Galantamine in the Treatment of Post-Traumatic Headache

NCT00219869
View directory record Official record
Conditions
Post-Traumatic Headache, Head Trauma,Closed, Retention Disorders,Cognitive
Interventions
Galantamine
Drug
Lead sponsor
Rapoport, Alan, M.D.
Individual
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Stamford, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 22, 2005 · Synced Oct 24, 2026, 1:50 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Elucidating the Role of Cholinergic Degeneration in Cognitive Fluctuations in Lewy Body Dementia

NCT07284290
View directory record Official record
Conditions
Dementia With Lewy Bodies, Parkinson Disease Dementia, Healthy Controls
Interventions
Syn-One skin biopsy, Multi modal MRI, Assessment of dynamic EEG features over 48-hour periods across all study aims, Plasma biomarkers, Galantamine HBr extended-release 8mg capsules (8mg ER).
Procedure · Diagnostic Test · Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
50 Years to 89 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 24, 2026, 1:50 AM EDT
Terminated Phase 2 Interventional Results available

Galantamine and Memantine Combination for Cognitive Impairments in Schizophrenia

NCT02234752
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Galantamine ER, Memantine XR
Drug
Lead sponsor
Sheppard Pratt Health System
Other
Eligibility
18 Years to 55 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 9, 2017 · Synced Oct 24, 2026, 1:50 AM EDT
Terminated Phase 4 Interventional

Safety Study of Galantamine in Tic Disorders

NCT00226824
View directory record Official record
Conditions
Tourette's Syndrome, Motor Tic Disorder, Vocal Tic Disorder
Interventions
galantamine
Drug
Lead sponsor
Parkinson's Disease and Movement Disorders Center
Other
Eligibility
18 Years to 50 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Aug 25, 2009 · Synced Oct 24, 2026, 1:50 AM EDT
Completed Phase 4 Interventional Results available

Olfactory Deficits and Donepezil Treatment in Cognitively Impaired Elderly

NCT01951118
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment, Delirium, Dementia, Amnestic, Cognitive Disorders
Interventions
Donepezil
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
55 Years to 95 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 13, 2020 · Synced Oct 24, 2026, 1:50 AM EDT
Completed Not applicable Interventional Results available

A Study to Help People Quit Smoking.

NCT01880099
View directory record Official record
Conditions
Nicotine Dependence
Interventions
placebo, Galantamine 8mg, Galantamine 16mg
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 23, 2020 · Synced Oct 24, 2026, 1:50 AM EDT
Active, not recruiting Phase 1 Interventional

Vagal Stimulation in POTS

NCT03124355
View directory record Official record
Conditions
Postural Tachycardia Syndrome
Interventions
placebo sugar pill, Pyridostigmine Pill, Galantamine Pill, Vagal stimulation, Sham vagal stimulation
Drug · Device
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 24, 2026, 1:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Low-Dose Galantamine to Potentiate the Attention-Enhancing Effects of Low-Dose Nicotine

NCT02420327
View directory record Official record
Conditions
Basic Science Study of the Mechanisms of Attentional Enhancement by Compounds Acting on the Nicotinic Receptor
Interventions
Placebo patch & placebo capsule, Placebo patch & galantamine capsule, Nicotine patch & placebo capsule, Nicotine patch and galantamine capsule
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
21 Years to 55 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 4, 2019 · Synced Oct 24, 2026, 1:50 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Racial Differences in Vagal Control of Glucose Homeostasis

NCT02365285
View directory record Official record
Conditions
Obesity
Interventions
Galantamine, Placebo Oral Capsule, Intralipid, Heparin
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 19, 2019 · Synced Oct 24, 2026, 1:50 AM EDT
Completed Phase 2 Interventional Results available

Effect of Galantamine on Short-term Abstinence

NCT01669538
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
Galantamine, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 60 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 15, 2019 · Synced Oct 24, 2026, 1:50 AM EDT
Recruiting Phase 2Phase 3 Interventional

Pilot Study of Galantamine to Treat Metabolic Syndrome in People With Chronic Traumatic Spinal Cord Injury (SCI)

NCT07625332
View directory record Official record
Conditions
Spinal Cord Injury, Traumatic Spinal Cord Injury, Paraplegia and Tetraplegia, Metabolic Syndrome
Interventions
Galantamine Hydrobromide Extended Release
Drug
Lead sponsor
Northwell Health
Other
Eligibility
21 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
West Orange, New Jersey • Manhasset, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 24, 2026, 1:50 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Enhancing Parasympathetic Activity to Improve Endothelial Dysfunction, Vascular Oxidative Stress in African Americans

NCT04769206
View directory record Official record
Conditions
Endothelial Dysfunction
Interventions
Galantamine, Placebo, TENS 7000
Drug · Device
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2028
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 24, 2026, 1:50 AM EDT
Completed Phase 2 Interventional Results available

Galantamine to Enhance Cognitive Behavioral Therapy for Cocaine Abuse

NCT00809835
View directory record Official record
Conditions
Cocaine Dependence
Interventions
Galantamine, Computer Assisted Cognitive Behavioral Therapy (CBT)
Drug · Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years to 50 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
2
States / cities
Bridgeport, Connecticut • Stratford, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 30, 2019 · Synced Oct 24, 2026, 1:50 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Subarachnoid Hemorrhage Recovery And Galantamine

NCT02872857
View directory record Official record
Conditions
Subarachnoid Hemorrhage
Interventions
Placebo, 8mg galantamine twice daily, 12mg galantamine twice daily
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 8, 2021 · Synced Oct 24, 2026, 1:50 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Galantamine Executive Function in Parkinson's Disease

NCT00211588
View directory record Official record
Conditions
Parkinson's Disease
Interventions
galantamine
Drug
Lead sponsor
Memorial Hospital of Rhode Island
Other
Eligibility
60 Years to 85 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
1
States / cities
Pawtucket, Rhode Island
Source: ClinicalTrials.gov public record
Updated May 7, 2007 · Synced Oct 24, 2026, 1:50 AM EDT
Completed Phase 4 Interventional Results available

Acetylcholinesterase Inhibitors to Improve Cognitive Function and Overall Rehabilitation After a Stroke

NCT00227994
View directory record Official record
Conditions
Cerebrovascular Accident
Interventions
Galantamine, Donepezil
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
60 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 11, 2017 · Synced Oct 24, 2026, 1:50 AM EDT
Completed Phase 4 Interventional Results available

Efficacy and Safety of Galantamine for Improving Dysfunction in People With Bipolar Disorder

NCT00741598
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Galantamine-ER, Galantamine placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
2
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated May 2, 2017 · Synced Oct 24, 2026, 1:50 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy of Galantamine in Patients With Dementia With Lewy Bodies

NCT00230997
View directory record Official record
Conditions
Lewy Body Disease
Interventions
Galantamine
Drug
Lead sponsor
Neurological Research Center
Industry
Eligibility
51 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
5
States / cities
Indianapolis, Indiana • Buffalo, New York • Pittsburgh, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2005 · Synced Oct 24, 2026, 1:50 AM EDT
Completed Phase 2 Interventional

A Study of RO4602522 in Participants With Moderate Severity Alzheimer Disease on Background Alzheimer Disease Therapy

NCT01677754
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
RO4602522, Placebo, Donepezil, Memantine, Rivastigmine, Galantamine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years to 90 Years
Enrollment
542 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
42
States / cities
Anaheim, California • Fullerton, California • Lomita, California + 36 more
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 24, 2026, 1:50 AM EDT
Terminated Phase 4 Interventional

Efficacy of Galantamine to Treat Schizophrenia

NCT00232349
View directory record Official record
Conditions
Schizophrenia, Psychotic Disorder
Interventions
galantamine
Drug
Lead sponsor
Seattle Institute for Biomedical and Clinical Research
Other
Eligibility
18 Years to 60 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jul 31, 2008 · Synced Oct 24, 2026, 1:50 AM EDT
Completed Not applicable Interventional

An Open-Label Investigation of the Adjuvant Therapeutic Effects of Galantamine in Patients With Chronic Schizophrenia and Persistent Deficit Symptoms

NCT00161044
View directory record Official record
Conditions
Chronic Schizophrenia
Interventions
Galantamine
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 17, 2022 · Synced Oct 24, 2026, 1:50 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

A Double-Blind, Placebo-Controlled Study of Galantamine to Improve Cognitive Dysfunction in Bipolar Disorder

NCT00195845
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Galantamine, Placebos
Drug
Lead sponsor
Cambridge Health Alliance
Other
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2007
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 18, 2017 · Synced Oct 24, 2026, 1:50 AM EDT
Completed Early Phase 1 Interventional Results available

Galantamine and CBT4CBT Pilot to Prevent Relapse.

NCT03547622
View directory record Official record
Conditions
Methadone or Buprenorphine Detoxoxification
Interventions
MAT taper with galantamine, MAT taper with placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 19, 2022 · Synced Oct 24, 2026, 1:50 AM EDT